Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
Idiopathic Giant Cell Myocarditis.

Current treatment options in cardiovascular medicine

Cooper LT, Okura Y.
PMID: 11696266
Curr Treat Options Cardiovasc Med. 2001 Dec;3(6):463-467. doi: 10.1007/s11936-001-0020-y.

Idiopathic giant cell myocarditis (IGCM) is an uncommon disorder that is of general importance because it most commonly affects young individuals, is usually fatal without treatment, and may respond to aggressive medical and surgical therapy. IGCM is most often...

Cite
Cooper LT, Okura Y. Idiopathic Giant Cell Myocarditis. Curr Treat Options Cardiovasc Med. 2001;3(6):463-467doi: 10.1007/s11936-001-0020-y.
Cooper, L. T., & Okura, Y. (2001). Idiopathic Giant Cell Myocarditis. Current treatment options in cardiovascular medicine, 3(6), 463-467. https://doi.org/10.1007/s11936-001-0020-y
Cooper, Leslie T., and Okura, Yuji. "Idiopathic Giant Cell Myocarditis." Current treatment options in cardiovascular medicine vol. 3,6 (2001): 463-467. doi: https://doi.org/10.1007/s11936-001-0020-y
Cooper LT, Okura Y. Idiopathic Giant Cell Myocarditis. Curr Treat Options Cardiovasc Med. 2001 Dec;3(6):463-467. doi: 10.1007/s11936-001-0020-y. PMID: 11696266.
Copy Download .nbib Format: NLM
Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis.

Crohn's & colitis 360

Boden EK, Canavan JB, Moran CJ, McCann K, Dunn WA, Farraye FA, Ananthakrishnan AN, Yajnik V, Gandhi R, Nguyen DD, Bhan AK, Weiner HL, Korzenik JR, Snapper SB.
PMID: 31423487
Crohns Colitis 360. 2019 Jul;1(2):otz009. doi: 10.1093/crocol/otz009. Epub 2019 Jun 07.

AIM: The aim of this study was to determine the immunologic effects and safety of oral anti-CD3 in patients with ulcerative colitis (UC).METHODS: An open-label pilot study of orally delivered anti-CD3 was performed in patients with moderate-to-severe UC. The...

Cite
Boden EK, Canavan JB, Moran CJ, et al. Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis. Crohns Colitis 360. 2019;1(2):otz009doi: 10.1093/crocol/otz009.
Boden, E. K., Canavan, J. B., Moran, C. J., McCann, K., Dunn, W. A., Farraye, F. A., Ananthakrishnan, A. N., Yajnik, V., Gandhi, R., Nguyen, D. D., Bhan, A. K., Weiner, H. L., Korzenik, J. R., & Snapper, S. B. (2019). Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis. Crohn's & colitis 360, 1(2), otz009. https://doi.org/10.1093/crocol/otz009
Boden, Elisa K, et al. "Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis." Crohn's & colitis 360 vol. 1,2 (2019): otz009. doi: https://doi.org/10.1093/crocol/otz009
Boden EK, Canavan JB, Moran CJ, McCann K, Dunn WA, Farraye FA, Ananthakrishnan AN, Yajnik V, Gandhi R, Nguyen DD, Bhan AK, Weiner HL, Korzenik JR, Snapper SB. Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis. Crohns Colitis 360. 2019 Jul;1(2):otz009. doi: 10.1093/crocol/otz009. Epub 2019 Jun 07. PMID: 31423487; PMCID: PMC6690423.
Copy Download .nbib Format: NLM
Long term management of liver transplant rejection in children.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Mazariegos GV, Salzedas AA, Zavatsky J, Sindhi R, Parizhskaya M, McGhee W, Jain A, Reyes J.
PMID: 18034554
BioDrugs. 2000 Jul;14(1):31-48. doi: 10.2165/00063030-200014010-00004.

The current management of hepatic allograft rejection after liver transplantation in children requires effective baseline immunosuppression to prevent rejection and rapid diagnosis and treatment to manage acute rejection episodes. The subsequent impact on chronic rejection is dependent on the...

Cite
Mazariegos GV, Salzedas AA, Zavatsky J, et al. Long term management of liver transplant rejection in children. BioDrugs. 2000;14(1):31-48doi: 10.2165/00063030-200014010-00004.
Mazariegos, G. V., Salzedas, A. A., Zavatsky, J., Sindhi, R., Parizhskaya, M., McGhee, W., Jain, A., & Reyes, J. (2000). Long term management of liver transplant rejection in children. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 14(1), 31-48. https://doi.org/10.2165/00063030-200014010-00004
Mazariegos, G V, et al. "Long term management of liver transplant rejection in children." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 14,1 (2000): 31-48. doi: https://doi.org/10.2165/00063030-200014010-00004
Mazariegos GV, Salzedas AA, Zavatsky J, Sindhi R, Parizhskaya M, McGhee W, Jain A, Reyes J. Long term management of liver transplant rejection in children. BioDrugs. 2000 Jul;14(1):31-48. doi: 10.2165/00063030-200014010-00004. PMID: 18034554.
Copy Download .nbib Format: NLM
Local graft irradiation for kidney allograft rejection: a case series and review of the literature.

Nephro-urology monthly

Fallahzadeh MK, Khan S, Zibari GB, Patil S, Singh N.
PMID: 25032135
Nephrourol Mon. 2014 Apr 28;6(3):e16262. doi: 10.5812/numonthly.16262. eCollection 2014 May.

INTRODUCTION: Due to its immunosuppressive properties, local graft irradiation (LGI) has been proposed as a second line therapy for treatment of acute kidney rejection.CASE PRESENTATION: In this case-series we report 6 patients with biopsy proven acute kidney allograft rejection...

Cite
Fallahzadeh MK, Khan S, Zibari GB, et al. Local graft irradiation for kidney allograft rejection: a case series and review of the literature. Nephrourol Mon. 2014;6(3):e16262doi: 10.5812/numonthly.16262.
Fallahzadeh, M. K., Khan, S., Zibari, G. B., Patil, S., & Singh, N. (2014). Local graft irradiation for kidney allograft rejection: a case series and review of the literature. Nephro-urology monthly, 6(3), e16262. https://doi.org/10.5812/numonthly.16262
Fallahzadeh, Mohammad Kazem, et al. "Local graft irradiation for kidney allograft rejection: a case series and review of the literature." Nephro-urology monthly vol. 6,3 (2014): e16262. doi: https://doi.org/10.5812/numonthly.16262
Fallahzadeh MK, Khan S, Zibari GB, Patil S, Singh N. Local graft irradiation for kidney allograft rejection: a case series and review of the literature. Nephrourol Mon. 2014 Apr 28;6(3):e16262. doi: 10.5812/numonthly.16262. eCollection 2014 May. PMID: 25032135; PMCID: PMC4090660.
Copy Download .nbib Format: NLM
Peripheral T-cell lymphoma immunophenotype in a patient with a history of Muromonab-CD3 therapy: A case report and a diagnostic dilemma.

Cytometry. Part B, Clinical cytometry

Hoffmann J, Klameth A, Russwurm M, Neubauer A, Brendel C.
PMID: 33955673
Cytometry B Clin Cytom. 2021 May 06; doi: 10.1002/cyto.b.22004. Epub 2021 May 06.

No abstract available.

Cite
Hoffmann J, Klameth A, Russwurm M, et al. Peripheral T-cell lymphoma immunophenotype in a patient with a history of Muromonab-CD3 therapy: A case report and a diagnostic dilemma. Cytometry B Clin Cytom. 2021;doi: 10.1002/cyto.b.22004.
Hoffmann, J., Klameth, A., Russwurm, M., Neubauer, A., & Brendel, C. (2021). Peripheral T-cell lymphoma immunophenotype in a patient with a history of Muromonab-CD3 therapy: A case report and a diagnostic dilemma. Cytometry. Part B, Clinical cytometry, . https://doi.org/10.1002/cyto.b.22004
Hoffmann, Joerg, et al. "Peripheral T-cell lymphoma immunophenotype in a patient with a history of Muromonab-CD3 therapy: A case report and a diagnostic dilemma." Cytometry. Part B, Clinical cytometry vol. (2021). doi: https://doi.org/10.1002/cyto.b.22004
Hoffmann J, Klameth A, Russwurm M, Neubauer A, Brendel C. Peripheral T-cell lymphoma immunophenotype in a patient with a history of Muromonab-CD3 therapy: A case report and a diagnostic dilemma. Cytometry B Clin Cytom. 2021 May 06; doi: 10.1002/cyto.b.22004. Epub 2021 May 06. PMID: 33955673.
Copy Download .nbib Format: NLM
Migraine Headache: Immunosuppressant Therapy.

Current treatment options in neurology

Rozen TD.
PMID: 12162928
Curr Treat Options Neurol. 2002 Sep;4(5):395-401. doi: 10.1007/s11940-002-0050-0.

There is very little literature on the use of immunosuppressant drugs in migraine treatment. Immunosuppressive agents are rarely, if ever, used as regular abortive drugs for episodic migraine attacks, and are never used as migraine preventives, because of the...

Cite
Rozen TD. Migraine Headache: Immunosuppressant Therapy. Curr Treat Options Neurol. 2002;4(5):395-401doi: 10.1007/s11940-002-0050-0.
Rozen, T. D. (2002). Migraine Headache: Immunosuppressant Therapy. Current treatment options in neurology, 4(5), 395-401. https://doi.org/10.1007/s11940-002-0050-0
Rozen, Todd D.. "Migraine Headache: Immunosuppressant Therapy." Current treatment options in neurology vol. 4,5 (2002): 395-401. doi: https://doi.org/10.1007/s11940-002-0050-0
Rozen TD. Migraine Headache: Immunosuppressant Therapy. Curr Treat Options Neurol. 2002 Sep;4(5):395-401. doi: 10.1007/s11940-002-0050-0. PMID: 12162928.
Copy Download .nbib Format: NLM
Infections in patients receiving OKT3 monoclonal antibody for cardiac rejection: results of a small clinical trial.

Texas Heart Institute journal

Sinnott JT, Cullison JP, Sweeney MS, Weinstein SS.
PMID: 15227260
Tex Heart Inst J. 1988;15(2):102-6.

Orthoclone OKT3 (muromonab-CD3), a murine monoclonal antibody that virtually eliminates circulating T cells and inhibits medullary lymphocyte function, has recently been found effective in reversing stubborn severe allograft rejection after heart transplantation. To determine the influence of OKT3 therapy...

Cite
Sinnott JT, Cullison JP, Sweeney MS, et al. Infections in patients receiving OKT3 monoclonal antibody for cardiac rejection: results of a small clinical trial. Tex Heart Inst J. 1988;15(2):102-6
Sinnott, J. T., Cullison, J. P., Sweeney, M. S., & Weinstein, S. S. (1988). Infections in patients receiving OKT3 monoclonal antibody for cardiac rejection: results of a small clinical trial. Texas Heart Institute journal, 15(2), 102-6.
Sinnott, J T, et al. "Infections in patients receiving OKT3 monoclonal antibody for cardiac rejection: results of a small clinical trial." Texas Heart Institute journal vol. 15,2 (1988): 102-6.
Sinnott JT, Cullison JP, Sweeney MS, Weinstein SS. Infections in patients receiving OKT3 monoclonal antibody for cardiac rejection: results of a small clinical trial. Tex Heart Inst J. 1988;15(2):102-6. PMID: 15227260; PMCID: PMC324800.
Copy Download .nbib Format: NLM
Renal-sparing immunosuppressive protocol using OKT3 after liver transplantation: a 19-year single-institution experience.

Proceedings (Baylor University. Medical Center)

Kim PT, Chinnakotla S, Davis G, Jennings LW, McKenna GJ, Onaca N, Ruiz RM, Goldstein R, Levy MF, Klintmalm GB.
PMID: 22046060
Proc (Bayl Univ Med Cent). 2011 Oct;24(4):287-94. doi: 10.1080/08998280.2011.11928740.

Different renal-sparing immunosuppressive protocols have been used in liver transplantation. At our institution, muromonab-CD3 (OKT3) is used in patients with acute renal failure (ARF), along with a delay in starting a calcineurin inhibitor. This study was conducted to compare...

Cite
Kim PT, Chinnakotla S, Davis G, et al. Renal-sparing immunosuppressive protocol using OKT3 after liver transplantation: a 19-year single-institution experience. Proc (Bayl Univ Med Cent). 2011;24(4):287-94doi: 10.1080/08998280.2011.11928740.
Kim, P. T., Chinnakotla, S., Davis, G., Jennings, L. W., McKenna, G. J., Onaca, N., Ruiz, R. M., Goldstein, R., Levy, M. F., & Klintmalm, G. B. (2011). Renal-sparing immunosuppressive protocol using OKT3 after liver transplantation: a 19-year single-institution experience. Proceedings (Baylor University. Medical Center), 24(4), 287-94. https://doi.org/10.1080/08998280.2011.11928740
Kim, Peter T W, et al. "Renal-sparing immunosuppressive protocol using OKT3 after liver transplantation: a 19-year single-institution experience." Proceedings (Baylor University. Medical Center) vol. 24,4 (2011): 287-94. doi: https://doi.org/10.1080/08998280.2011.11928740
Kim PT, Chinnakotla S, Davis G, Jennings LW, McKenna GJ, Onaca N, Ruiz RM, Goldstein R, Levy MF, Klintmalm GB. Renal-sparing immunosuppressive protocol using OKT3 after liver transplantation: a 19-year single-institution experience. Proc (Bayl Univ Med Cent). 2011 Oct;24(4):287-94. doi: 10.1080/08998280.2011.11928740. PMID: 22046060; PMCID: PMC3205150.
Copy Download .nbib Format: NLM
Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.

Journal of fungi (Basel, Switzerland)

Kyriakidis I, Vasileiou E, Rossig C, Roilides E, Groll AH, Tragiannidis A.
PMID: 33807678
J Fungi (Basel). 2021 Mar 05;7(3). doi: 10.3390/jof7030186.

Since 1985 when the first agent targeting antigens on the surface of lymphocytes was approved (muromonab-CD3), a multitude of such therapies have been used in children with hematologic malignancies. A detailed literature review until January 2021 was conducted regarding...

Cite
Kyriakidis I, Vasileiou E, Rossig C, et al. Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. J Fungi (Basel). 2021;7(3)doi: 10.3390/jof7030186.
Kyriakidis, I., Vasileiou, E., Rossig, C., Roilides, E., Groll, A. H., & Tragiannidis, A. (2021). Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. Journal of fungi (Basel, Switzerland), 7(3), . https://doi.org/10.3390/jof7030186
Kyriakidis, Ioannis, et al. "Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies." Journal of fungi (Basel, Switzerland) vol. 7,3 (2021). doi: https://doi.org/10.3390/jof7030186
Kyriakidis I, Vasileiou E, Rossig C, Roilides E, Groll AH, Tragiannidis A. Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. J Fungi (Basel). 2021 Mar 05;7(3). doi: 10.3390/jof7030186. PMID: 33807678; PMCID: PMC7999508.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 12224444
Methods Find Exp Clin Pharmacol. 2002 Jul-Aug;24(6):371-91.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002;24(6):371-91
Bayés, M., Rabasseda, X., & Prous, J. R. (2002). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 24(6), 371-91.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 24,6 (2002): 371-91.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Jul-Aug;24(6):371-91. PMID: 12224444.
Copy Download .nbib Format: NLM
Guidelines for the optimal use of muromonab CD3 in transplantation.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

ten Berge IJ, Parlevliet KJ, Raasveld MH, Buysmann S, Bemelman FJ, Schellekens PT.
PMID: 18031137
BioDrugs. 1999 Apr;11(4):277-84. doi: 10.2165/00063030-199911040-00006.

Muromonab CD3 (OKT3), the murine anti-CD3 monoclonal antibody (mAb) of the IgG-2a class, directed against the CD3 molecule on the surface of human T cells, has proven to be a powerful immunosuppressive agent in solid organ transplantation and has...

Cite
ten Berge IJ, Parlevliet KJ, Raasveld MH, et al. Guidelines for the optimal use of muromonab CD3 in transplantation. BioDrugs. 1999;11(4):277-84doi: 10.2165/00063030-199911040-00006.
ten Berge, I. J., Parlevliet, K. J., Raasveld, M. H., Buysmann, S., Bemelman, F. J., & Schellekens, P. T. (1999). Guidelines for the optimal use of muromonab CD3 in transplantation. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 11(4), 277-84. https://doi.org/10.2165/00063030-199911040-00006
ten Berge, I J, et al. "Guidelines for the optimal use of muromonab CD3 in transplantation." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 11,4 (1999): 277-84. doi: https://doi.org/10.2165/00063030-199911040-00006
ten Berge IJ, Parlevliet KJ, Raasveld MH, Buysmann S, Bemelman FJ, Schellekens PT. Guidelines for the optimal use of muromonab CD3 in transplantation. BioDrugs. 1999 Apr;11(4):277-84. doi: 10.2165/00063030-199911040-00006. PMID: 18031137.
Copy Download .nbib Format: NLM
Monoclonal antibody-induced cytokine-release syndrome.

Expert review of clinical immunology

Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman-Thio E.
PMID: 20477639
Expert Rev Clin Immunol. 2009 Sep;5(5):499-521. doi: 10.1586/eci.09.31.

Monoclonal antibodies (mAbs) are widely used in anti-inflammatory and tumor therapy. Although effective, mAbs can cause a variety of adverse effects. An important toxicity seen with a few mAbs is cytokine-release syndrome (CRS). These mAbs include: alemtuzumab, muromonab-CD3, rituximab,...

Cite
Bugelski PJ, Achuthanandam R, Capocasale RJ, et al. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol. 2009;5(5):499-521doi: 10.1586/eci.09.31.
Bugelski, P. J., Achuthanandam, R., Capocasale, R. J., Treacy, G., & Bouman-Thio, E. (2009). Monoclonal antibody-induced cytokine-release syndrome. Expert review of clinical immunology, 5(5), 499-521. https://doi.org/10.1586/eci.09.31
Bugelski, Peter J, et al. "Monoclonal antibody-induced cytokine-release syndrome." Expert review of clinical immunology vol. 5,5 (2009): 499-521. doi: https://doi.org/10.1586/eci.09.31
Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman-Thio E. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol. 2009 Sep;5(5):499-521. doi: 10.1586/eci.09.31. PMID: 20477639.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries